US-based Acelity has purchased exclusive worldwide rights of the Revolve System from The GID Group, for an undisclosed amount.
The Revolve System is a fat processing technology used in both reconstructive and cosmetic procedures to facilitate high-volume and autologous fat grafting.
Acelity company LifeCell was granted exclusive rights to distribute the system in the US and Canada since 2013, while the new deal provides the company with worldwide rights for development, manufacturing and commercialization of the device.
Acelity chief medical officer Dr Ron Silverman said: "We are looking forward to working with the plastic surgery community to further develop the Revolve System and bring its clinical and economic benefits to patients around the world.
"It aligns with our strategy of broadening our regenerative medicine portfolio of products for plastic surgeons by providing solutions that go beyond acellular dermal matrix procedures."
The Revolve system has been developed to provide rapid and reliable results in high-volume procedures through the use of a closed system that controls critical variables in the procedure.
The GID Group co-founder and plastic surgeon Adam Katz said: "Fat grafting use among plastic surgeons is growing, but there remain many opportunities to improve the way it is performed, particularly in large volume breast procedures."